Article Sidebar

PDF
Issue: Vol. 563 No. 1 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v563i1.18917
Date Published: 15/09/2026
Views 0
Downloads 0
How to Cite
Nguyễn, T. N., Hoàng, M. T., Vũ, V. S., & Nguyễn, T. T. H. (2026). CLINICAL AND PARACLINICAL CHARACTERISTICS AND INITIAL TREATMENT OUTCOMES OF STAGE IV THYMIC CARCINOMA WITH FIRST-LINE PACLITAXEL-CARBOPLATIN REGIMEN. Vietnam Medical Journal, 563(1). https://doi.org/10.51298/vmj.v563i1.18917

CLINICAL AND PARACLINICAL CHARACTERISTICS AND INITIAL TREATMENT OUTCOMES OF STAGE IV THYMIC CARCINOMA WITH FIRST-LINE PACLITAXEL-CARBOPLATIN REGIMEN

Thị Ngọc Nguyễn1, , Mạnh Thắng Hoàng1,2, Văn Sơn Vũ3, Thị Thái Hòa Nguyễn2
1 Trường Đại học Y Hà Nội
2 Bệnh viện K
3 Học viện Quân y

Main Article Content

Abstract

Objectives: To describe the clinical and paraclinical characteristics, objective response rate, and adverse effects of stage IV thymic carcinoma treated with first-line Paclitaxel–Carboplatin (PC) regimen.


Subjects and Methods: A retrospective study of 59 patients with stage IV thymic carcinoma (WHO 2021; TNM version 9), Eastern Cooperative Oncology Group (ECOG) performance status 0–1, treated with first-line PC regimen from January 2016 to December 2025 at K Hospital and National Lung Hospital. Treatment response was assessed according to RECIST 1.1 and toxicity according to CTCAE v5.0.


Results: Mean age 52.7 ± 14.8 years; male 67.8%; ECOG 0: 54.2%. Chest pain (50.8%), cough (35.6%), and fatigue (33.9%) were the most common symptoms. Squamous cell carcinoma accounted for 66.1%; stage IVB 64.4%; pleural metastasis 47.5%. No complete response (CR) was achieved; partial response (PR) 45.8%, stable disease (SD) 39%, and progressive disease (PD) 15.2%. Objective response rate (ORR) was 45.8% and disease control rate (DCR) was 84.8%. Common toxicities included anemia (62.7%), peripheral neuropathy (52.5%), and leukopenia (45.8%), predominantly grade 1–2; no grade 4 toxicity and no treatment-related mortality were recorded.


Conclusions: The Paclitaxel–Carboplatin regimen achieved a moderate response rate with an acceptable safety profile, consistent with the NCCN v2.2026 priority recommendation for stage IV thymic carcinoma.

Keywords

stage IV thymic carcinoma, Paclitaxel–Carboplatin, clinical and paraclinical characteristics, objective response rate, adverse effects

Article Details

References

1. Detterbeck FC, Zeeshan A, Asamura H, et al. Thymic Carcinomas: a concise multidisciplinary update from the Thymic Carcinoma Working Group of ITMIG. J Thorac Oncol. 2022;17(4):455-468.
2. Fang W, Detterbeck F, Ackman JB, et al. International Thymic Malignancy Interest Group Standard Definitions, Policies, and Reporting Measures for Thymic Epithelial Tumors. J Thorac Oncol. 2026;21(1):102-111.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas. Version 2.2026. Fort Washington, PA: NCCN; 2026.
4. Furugen M, Sekine I, Tsuta K, et al. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer. Jpn J Clin Oncol. 2011;41(8):1013-1016.
5. Hirai F, Yamanaka T, Taguchi K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol. 2015;26(2):363-368.
6. Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011;29(15):2060-2065.
7. Đào Minh Thế, Đỗ Hùng Kiên. Đánh giá kết quả điều trị phác đồ Paclitaxel-Carboplatin trên bệnh nhân ung thư biểu mô tuyến ức giai đoạn IV không còn khả năng phẫu thuật. Tạp chí Y học Việt Nam. 2023;533(1B):1-5.
8. Bùi Xuân Thắng, Nguyễn Thị Thái Hòa, Vũ Hà Thanh, và cs. Results of chemotherapy Paclitaxel-Carboplatin treatment in metastatic thymic carcinoma at K Hospital. Tạp chí Ung thư học Việt Nam. 2025;78(1):6-11.